USA FDA Gives Biogen Big Hand In Effort To Get Its Alzheimer’s Treatment On The Market

In unusual move, FDA formed ‘working group’ collaboration with Biogen to conduct further analyses of two aducanumab studies after the Phase III trials were halted. Agency concluded drug’s effectiveness in one of the studies is ‘robust and exceptionally persuasive’ and advised Biogen that it was ‘reasonable’ to submit a marketing application.

Silhouettes of two people climbing on mountain and helping
FDA collaborates with Biogen in preparting aducanumab Alzheimer's drug for BLA submission • Source: Shutterstock

The US Food and Drug Administration has a lot at stake in the outcome of an advisory committee review of Biogen, Inc.’s Alzheimer’s disease drug aducanumab given how much help it gave the company in pursuing approval despite the negative results of one of two Phase III studies.

The agency revealed its close collaboration with Biogen in a joint briefing document for the 6 November meeting of...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers